Search: id:"swepub:oai:DiVA.org:uu-181680" >
Phase II study of p...
Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy
-
- Hultman, Bo (author)
- Uppsala universitet,Kolorektalkirurgi
-
- Lind, Pehr (author)
- Karolinska Institutet
-
- Glimelius, Bengt (author)
- Uppsala universitet,Enheten för onkologi
-
show more...
-
- Sundbom, Magnus (author)
- Uppsala universitet,Gastrointestinalkirurgi
-
- Nygren, Peter (author)
- Uppsala universitet,Enheten för onkologi
-
- Haglund, Ulf (author)
- Uppsala universitet,Gastrointestinalkirurgi
-
- Mahteme, Haile (author)
- Uppsala universitet,Kolorektalkirurgi
-
show less...
-
(creator_code:org_t)
- 2013
- 2013
- English.
-
In: Acta Oncologica. - 0284-186X .- 1651-226X. ; 52:4, s. 824-830
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.3...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- BackgroundThe aim was to evaluate the feasibility and the effectiveness of neoadjuvant systemic chemotherapy followed by cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC) in patients with peritoneal carcinomatosis (PC) from gastric cancer.Material and methodsEighteen patients (median age 57 years, range 38-74) were scheduled for three months' neoadjuvant systemic chemotherapy followed by CRS + HIPEC + EPIC.ResultsAt the time of surgery, the peritoneal tumor burden was extensive with tumor growth on the entire peritoneal cavity. Only eight patients received the entire treatment and OS was 14.3 months (range 6.1-34.3, 95% CI 6.6-20.3). Six patients had macroscopically radical (CC0) surgery and for this subgroup OS was 19.1 months (range 6.1-34.3, 95% CI 6.9-27.1). Postoperative 90-day mortality was 10% (one patient) and the perioperative grades II-IV adverse events (AE) rate was 62.5%.DiscussionNeoadjuvant chemotherapy followed by CRS + HIPEC + EPIC does not seem to be associated with prolonged OS in patients with extensive PC growth from gastric cancer unless macroscopically radical surgery is achieved. However, morbidity from this treatment is considerable and it cannot be recommended for routine care until a prospective randomized trial has been performed.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Keyword
- gastric cancer
- peritoneal carcinomatosis
- neoadjuvant chemotherapy
- cytoreductive surgery
- HIPEC
- Kirurgi
- Surgery
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database